

# PBTQ

As of Dec. 31, 2009


## Fund Description

The PowerShares Global Biotech Portfolio is based on the NASDAQ OMX Global Biotechnology Index<sup>SM</sup>. The Fund will normally invest at least 90% of its total assets in securities that comprise the Index and American depository receipts and global depository receipts based on the securities in the Index. The Index is designed to measure the overall performance of globally traded securities of the largest and most liquid companies involved in the biotechnology industry. The Index is rebalanced quarterly using a modified, market-cap-weighted methodology.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks. Ordinary brokerage commissions apply. Concentrated industry investments involve greater risks than more diversified investments.

## PowerShares Global Biotech Portfolio

### Growth of \$10,000<sup>1</sup>



### Fund Performance & Index History (%)<sup>1</sup>

	1 Year	3 Year	5 Year	10 Year	Fund Inception <sup>2</sup>
<b>Underlying Index</b>					
NASDAQ OMX Global Biotechnology	6.49	-	-	-	-4.65
<b>Benchmark Indexes</b>					
MSCI EAFE	31.78	-	-	-	4.36
S&P 500	26.47	-	-	-	-1.03
<b>Fund</b>					
NAV	7.45	-	-	-	-4.58
After Tax Held	7.45	-	-	-	-4.58
After Tax Sold	4.85	-	-	-	-3.89
Market Price	7.61	-	-	-	-5.09

### Fund Data<sup>3</sup>

Global Biotech Portfolio	PBTQ
Intraday NAV (IIV)	PBTQ.IV

### Underlying Index Data

NASDAQ OMX Global Biotechnology	QGBI
Index Provider	NASDAQ OMX Group Inc.

### 1-Year Alpha, Beta and Correlation<sup>1,3</sup>

Data shown are that of the underlying Index relative to each respective benchmark index.

	Alpha	Beta	Correlation
MSCI EAFE	-2.72	0.37	0.17
S&P 500	-7.29	0.61	0.52

Performance data quoted represents past performance. As stated in the Fund's prospectus, the expense ratio of 0.75% is expressed as a unitary fee to cover expenses incurred in connection with managing the portfolio. Past performance is not a guarantee of future results; current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and Shares, when redeemed, may be worth more or less than their original cost. See [invescopowershares.com](http://invescopowershares.com) to find the most recent month-end performance numbers. After Tax Held represents total return after taxes on distributions and assumes Shares have not been sold. After Tax Sold represents total return after taxes on distributions and the sale of Fund Shares. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times.

### 1-Year Index Statistics<sup>1,3</sup>

	Performance (%)	Volatility (%)	Sharpe Ratio
NASDAQ OMX Global Biotechnology	6.49	22.78	0.27
MSCI EAFE	31.78	25.21	1.24
S&P 500	26.47	27.17	0.96

### Fund Inception: Sept. 18, 2008

<sup>1</sup> Index returns do not represent Fund returns. An investor cannot invest directly in an index.

<sup>2</sup> Returns for the benchmark indexes are based on the closest month end to the Fund's inception date. Fund performance figures include the reinvestment of dividends but the return figures for the respective underlying Index do not. As a result, Fund performance returns may appear to be more favorable when compared to the underlying Index's returns.

Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of the indexes lend securities, and no revenues from securities lending were added to the performance

shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund.


The MSCI EAFE<sup>®</sup> Index and the S&P 500<sup>®</sup> Index are unmanaged indexes considered representative of stocks of Europe, Australasia and the Far East; and the U.S. stock market, respectively.

**Shares are not FDIC insured, may lose value and have no bank guarantee.**

**Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 50,000 Shares.**

As of Dec. 31, 2009

Top 30 Fund Holdings (%) <sup>4</sup> Name	Weight
CSL Ltd.	7.83
Celgene Corp.	7.77
Amgen Inc.	7.77
Genzyme Corp.	7.48
Gilead Sciences Inc.	7.27
Biogen Idec Inc.	4.41
Vertex Pharmaceuticals Inc.	4.27
Human Genome Sciences Inc.	4.25
Cephalon Inc.	4.09
Alexion Pharmaceuticals Inc.	3.77
Actelion Ltd.	3.51
Grifols SA	3.28
Dendreon Corp.	3.01
United Therapeutics Corp.	2.46
Myriad Genetics Inc.	2.20
Amylin Pharmaceuticals Inc.	1.76
Regeneron Pharmaceuticals Inc.	1.70
BioMarin Pharmaceutical Inc.	1.66
Onyx Pharmaceuticals Inc.	1.59
OSI Pharmaceuticals Inc.	1.58
Intercell AG	1.54
Crucell N.V.	1.15
Medivation Inc.	1.11
Zeltia S.A.	1.08
Cubist Pharmaceuticals Inc.	0.96
Isis Pharmaceuticals Inc.	0.96
Incyte Corp.	0.95
Seattle Genetics Inc.	0.89
Acorda Therapeutics Inc.	0.84
Savient Pharmaceuticals Inc.	0.79



**Fund Details<sup>3</sup>**

Weighted Harmonic Average Stock Price-to-Earnings Ratio	16.68
Weighted Harmonic Average Stock Price-to-Book-Value Ratio	3.55
Weighted Average Return on Equity	2.32
Weighted Market Cap (mm)	14,096
Approximate Number of Securities	44
Expense Ratio	0.75%
CUSIP	73936Q801
Listing Exchange	NASDAQ

**Fund Sector Allocations (%)**

Consumer Discretionary	-
Consumer Staples	-
Energy	-
Financials	-
Health Care	100.00
Industrials	-
Information Technology	-
Materials	-
Telecommunication Services	-
Utilities	-

**Annual Index Performance (%)**

	NASDAQ OMX		S&P 500
	Global Biotechnology	MSCI EAFE	
2009	6.49	31.78	26.47

**Fund Market-Cap Allocations (%)**

Large-Cap Growth	46.03
Large-Cap Value	-
Mid-Cap Growth	27.64
Mid-Cap Value	-
Small-Cap Growth	26.33
Small-Cap Value	-

**Fund Country Allocations (%)**

United States	79.54
Australia	7.83
Spain	4.36
Switzerland	4.03
Austria	1.54
Netherlands	1.15
Denmark	0.62
United Kingdom	0.57
France	0.35

## Leading the Intelligent ETF Revolution®

Underlying Index performance does not represent Fund performance.

<sup>3</sup> The Intraday NAV is a symbol representing estimated fair value based on the most recent intraday price of underlying assets.

Volatility is the annualized standard deviation of monthly index returns.

Beta is a measure of relative risk and the slope of regression.

Sharpe Ratio is a risk-adjusted measure calculated using standard deviation and excess return to determine reward per unit of risk. A higher Sharpe Ratio indicates better risk-adjusted performance.

Correlation indicates the degree to which two investments have historically moved in the same direction and magnitude.

Alpha is a measure of performance on a risk-adjusted basis.

Stock Price-to-Earnings Ratio is the share price divided by earnings per share. It is measured on a 12-month trailing basis.

Stock Price-to-Book-Value Ratio is the ratio of a stock's market price to a company's net asset value.

Weighted Harmonic Average is a method of calculating an average value that lessens the impact of large outliers and increases the impact of small ones.

Weighted Average Return on Equity is net income divided by net worth.

Weighted Market Capitalization is the sum of each underlying securities' market value.

<sup>4</sup> Please see the website for complete holdings information. Holdings are subject to change.

Investment in the securities of non-U.S. issuers involves risks beyond those associated with investments in U.S. securities, including, but not limited to, greater market volatility, the availability of less reliable financial information, higher transactional costs, taxation by foreign governments, decreased market liquidity, political instability, changes in currency exchange rates, interest rate fluctuation and monetary policy changes.

**Investments focused in a particular industry are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.**

Shares are subject to risks including: Small and Medium-Sized Company Risk – investing in securities of small and medium-sized companies involves greater risk than is customarily associated with investing in more established companies.

PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC. NASDAQ®, OMX™ and NASDAQ OMX Global Biotechnology Index<sup>SM</sup> are trade/service marks of The NASDAQ OMX Group, Inc. (which with its affiliates is referred to as the "Corporations") and are licensed for use

by Invesco PowerShares. The Product has not been passed on by the Corporations as to its legality or suitability. The Product is not issued, endorsed, sold or promoted by the Corporations. **The Corporations make no warranties and bear no liability with respect to the product.**

**Invesco Aim Distributors, Inc. is the distributor of the PowerShares Exchange-Traded Fund Trust II.**

**Invesco PowerShares Capital Management LLC and Invesco Aim Distributors, Inc. are indirect, wholly owned subsidiaries of Invesco Ltd.**

**An investor should consider the Fund's investment objective, risks, charges and expenses carefully before investing. For this and more complete information about the Fund call 800 983 0903 or visit [www.invescopowershares.com](http://www.invescopowershares.com) for a prospectus. Please read the prospectus carefully before investing.**

Note: Not all products available through all firms.